JP3904238B2
(ja)
*
|
1996-03-20 |
2007-04-11 |
イムノメディクス, インコーポレイテッド |
グリコシル化されたヒト化b細胞特異的抗体
|
US6953675B2
(en)
|
1997-11-06 |
2005-10-11 |
Immunomedics, Inc. |
Landscaped antibodies and antibody fragments for clinical use
|
US6962702B2
(en)
|
1998-06-22 |
2005-11-08 |
Immunomedics Inc. |
Production and use of novel peptide-based agents for use with bi-specific antibodies
|
US8383081B2
(en)
*
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
US7829064B2
(en)
*
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
US8119101B2
(en)
|
1999-05-10 |
2012-02-21 |
The Ohio State University |
Anti-CD74 immunoconjugates and methods of use
|
WO2001061351A1
(fr)
*
|
2000-02-17 |
2001-08-23 |
Laboratory Of Molecular Biophotonics |
Detection d'antigene par voie quantitative
|
US7321026B2
(en)
|
2001-06-27 |
2008-01-22 |
Skytech Technology Limited |
Framework-patched immunoglobulins
|
KR101027889B1
(ko)
*
|
2001-10-15 |
2011-04-07 |
아이비씨 파마슈티컬스, 인코퍼레이티드 |
친화력 증강제
|
JP2005507659A
(ja)
*
|
2001-10-15 |
2005-03-24 |
イミューノメディクス、インコーポレイテッド |
直接ターゲッティング結合タンパク質
|
US7393648B2
(en)
|
2001-12-03 |
2008-07-01 |
Alexion Pharmaceuticals, Inc. |
Hybrid antibodies
|
DK1461428T3
(da)
*
|
2001-12-03 |
2012-06-04 |
Alexion Pharma Inc |
Fremgangsmåde til at fremstille hybridantistoffer
|
IL162732A0
(en)
*
|
2001-12-26 |
2005-11-20 |
Immunomedics Inc |
Methods of generating multispecific, multivalent agents from hv and vl domains
|
CN100522999C
(zh)
*
|
2002-02-14 |
2009-08-05 |
免疫医疗公司 |
抗cd20抗体及其融合蛋白和使用方法
|
US8287864B2
(en)
*
|
2002-02-14 |
2012-10-16 |
Immunomedics, Inc. |
Structural variants of antibodies for improved therapeutic characteristics
|
WO2003072736A2
(en)
*
|
2002-02-21 |
2003-09-04 |
Duke University |
Reagents and treatment methods for autoimmune diseases
|
US7238785B2
(en)
|
2002-03-01 |
2007-07-03 |
Immunomedics, Inc. |
RS7 antibodies
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
ATE477276T1
(de)
|
2002-03-01 |
2010-08-15 |
Immunomedics Inc |
Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
MXPA04012656A
(es)
|
2002-06-14 |
2005-08-15 |
Immunomedics Inc |
Anticuerpo hpam4 monoclonal humanizado.
|
US7300655B2
(en)
|
2002-08-01 |
2007-11-27 |
Immunomedics, Inc. |
Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof
|
US7541440B2
(en)
|
2002-09-30 |
2009-06-02 |
Immunomedics, Inc. |
Chimeric, human and humanized anti-granulocyte antibodies and methods of use
|
EP2308968A1
(de)
*
|
2002-11-26 |
2011-04-13 |
Genentech, Inc. |
Zusammensetzung und Verfahren zur Behandlung von Immunerkrankungen
|
US8420086B2
(en)
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
US7534427B2
(en)
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
JP4733635B2
(ja)
|
2003-07-31 |
2011-07-27 |
イミューノメディクス、インコーポレイテッド |
抗cd19抗体
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
EP2053062A1
(de)
|
2004-03-24 |
2009-04-29 |
Xencor, Inc. |
Immunoglobinvarianten außerhalb der Fc-Region
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
EP2314618A3
(de)
|
2004-11-12 |
2011-10-19 |
Xencor Inc. |
Fc-Varianten mit modifizierter Bindung an FcRn
|
EP3332808B1
(de)
|
2005-03-03 |
2020-09-09 |
Immunomedics Inc. |
Humanisierte l243-antikörper
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
JP5057967B2
(ja)
|
2005-03-31 |
2012-10-24 |
中外製薬株式会社 |
sc(Fv)2構造異性体
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
KR101367544B1
(ko)
|
2005-06-10 |
2014-02-26 |
추가이 세이야쿠 가부시키가이샤 |
메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
|
JP5085322B2
(ja)
|
2005-06-10 |
2012-11-28 |
中外製薬株式会社 |
sc(Fv)2を含有する医薬組成物
|
KR20080025174A
(ko)
|
2005-06-23 |
2008-03-19 |
메디뮨 인코포레이티드 |
응집 및 단편화 프로파일이 최적화된 항체 제제
|
US20070190047A1
(en)
*
|
2005-07-29 |
2007-08-16 |
Amgen, Inc. |
Formulations that inhibit protein aggregation
|
CA2624189A1
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
CA2625998C
(en)
|
2005-10-06 |
2015-12-01 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
WO2007061936A2
(en)
*
|
2005-11-18 |
2007-05-31 |
New England Medical Center Hospitals, Inc. |
Clearance of abnormal iga1 in iga1 deposition diseases
|
EP2650306A1
(de)
|
2006-03-06 |
2013-10-16 |
Aeres Biomedical Limited |
Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
|
EP1998799B8
(de)
|
2006-03-06 |
2014-03-05 |
Medlmmune, LLC |
Humanisierte anti-cd22-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
|
DK2383297T5
(da)
|
2006-08-14 |
2022-07-04 |
Xencor Inc |
Optimerede antistoffer rettet mod CD19
|
CA2660795C
(en)
|
2006-09-18 |
2014-11-18 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
EP2896630B1
(de)
|
2007-01-30 |
2020-12-23 |
Epivax, Inc. |
Regulatorische t-zellen-epitope sowie zusammensetzungen damit und anwendungen davon
|
ES2742268T3
(es)
|
2007-12-26 |
2020-02-13 |
Xencor Inc |
Variantes de Fc con unión alterada a FcRn
|
CN102159243B
(zh)
*
|
2008-07-21 |
2015-08-19 |
免疫医疗公司 |
用于改良的治疗特征的抗体的结构变体
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
EP3939617A1
(de)
|
2009-02-13 |
2022-01-19 |
Immunomedics, Inc. |
Konjugate mit einer intrazellulär spaltbaren bindung
|
WO2010096394A2
(en)
|
2009-02-17 |
2010-08-26 |
Redwood Biosciences, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
WO2010123885A2
(en)
|
2009-04-20 |
2010-10-28 |
Tufts Medical Center, Inc. |
Iga1 protease polypeptide agents and uses thereof
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
KR20120104517A
(ko)
*
|
2009-09-03 |
2012-09-21 |
제넨테크, 인크. |
류마티스 관절염의 치료, 진단 및 모니터링 방법
|
CA2774260C
(en)
|
2009-09-16 |
2018-10-09 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
IN2012DN03354A
(de)
|
2009-12-02 |
2015-10-23 |
Immunomedics Inc |
|
EP2523680A4
(de)
*
|
2010-01-11 |
2013-06-19 |
Ct Molecular Med & Immunology |
Verstärkte zytotoxizität von antikörpern gegen cd74 und hla-dr mit interferon-gamma
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
CA2824143C
(en)
|
2011-01-14 |
2018-12-18 |
Redwood Bioscience, Inc. |
Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
|
RU2013140975A
(ru)
|
2011-02-28 |
2015-04-10 |
Дженентек, Инк. |
Биологические маркеры и способы прогнозирования восприимчивости к антагонистам в-клеток
|
CN107115526A
(zh)
|
2011-05-02 |
2017-09-01 |
免疫医疗公司 |
用于小体积施用的同种异型选择的抗体的超滤浓缩
|
US20150299313A1
(en)
*
|
2011-10-05 |
2015-10-22 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting clearance from plasma of antigen comprising suger chain receptor-binding domain
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
WO2013085893A1
(en)
|
2011-12-05 |
2013-06-13 |
Immunomedics, Inc. |
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
|
AU2013290424B2
(en)
|
2012-07-19 |
2018-01-25 |
Redwood Bioscience, Inc. |
Antibody specific for CD22 and methods of use thereof
|
CA2874864C
(en)
|
2012-08-14 |
2023-02-21 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
WO2015012904A2
(en)
|
2012-12-13 |
2015-01-29 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
CA2884313C
(en)
|
2012-12-13 |
2023-01-03 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
SG10201809779RA
(en)
*
|
2013-03-11 |
2018-12-28 |
Genzyme Corp |
Site-specific antibody-drug conjugation through glycoengineering
|
DK2991683T3
(da)
|
2013-05-02 |
2019-11-04 |
Glykos Finland Oy |
Konjugater af et glykoprotein eller en glykan med en toksisk ladning
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
KR20160054501A
(ko)
|
2013-08-26 |
2016-05-16 |
맵백스 테라퓨틱스, 인코포레이티드 |
시알릴-루이스 a에 대한 사람 항체 코드화 핵산
|
WO2015057064A1
(en)
|
2013-10-14 |
2015-04-23 |
Synaffix B.V. |
Modified glycoprotein, protein-conjugate and process for the preparation thereof
|
US20160235861A1
(en)
|
2013-10-14 |
2016-08-18 |
SynAffix. B.V. |
Glycoengineered antibody, antibody-conjugate and methods for their preparation
|
EP3929301A1
(de)
|
2013-10-14 |
2021-12-29 |
SynAffix B.V. |
Durch glyco-engineering hergestellter antikörper, antikörperkonjugat und verfahren zu deren herstellung
|
MX2016010683A
(es)
|
2014-02-21 |
2017-05-11 |
Ibc Pharmaceuticals Inc |
Terapia para tratar enfermedades mediante la induccion de respuesta inmune de las células que expresan trop-2.
|
CA2935748A1
(en)
|
2014-02-25 |
2015-09-03 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
NZ764877A
(en)
|
2014-06-04 |
2023-12-22 |
Biontech Res And Development Inc |
Human monoclonal antibodies to ganglioside gd2
|
CA2953567C
(en)
|
2014-06-24 |
2023-09-05 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
WO2015197919A1
(en)
|
2014-06-25 |
2015-12-30 |
Glykos Finland Oy |
Antibody drug conjugates binding to high-mannose n-glycan
|
EP3160513B1
(de)
|
2014-06-30 |
2020-02-12 |
Glykos Finland Oy |
Saccharidderivat einer toxischen nutzlast und antikörperkonjugate davon
|
CN106999517A
(zh)
|
2014-10-07 |
2017-08-01 |
免疫医疗公司 |
抗体‑药物缀合物的新辅助剂用途
|
CN107428837A
(zh)
|
2015-04-22 |
2017-12-01 |
免疫医疗公司 |
循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
PL3313443T3
(pl)
|
2015-06-25 |
2023-11-06 |
Immunomedics, Inc. |
Łączenie przeciwciał anty-hla-dr lub anty-trop-2 z inhibitorami mikrotubuli, inhibitorami parp, 5 inhibitorami kinazy brutona lub inhibitorami 3-kinazy fosfoinozytydu istotnie poprawia wynik terapeutyczny nowotworu
|
EP3316885B1
(de)
|
2015-07-01 |
2021-06-23 |
Immunomedics, Inc. |
Antikörper-sn-38-immunkonjugate mit einem cl2a-linker
|
US20170224837A1
(en)
|
2016-02-10 |
2017-08-10 |
Immunomedics, Inc. |
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
|
US11208632B2
(en)
|
2016-04-26 |
2021-12-28 |
R.P. Scherer Technologies, Llc |
Antibody conjugates and methods of making and using the same
|
EP3448260A4
(de)
|
2016-04-27 |
2019-10-09 |
Immunomedics, Inc. |
Wirksamkeit von anti-trop-2-sn-38-antikörper-wirkstoff-konjugaten zur therapie von rezidivierten/refraktären tumoren gegen checkpoint-inhibitoren
|
EP3468587A4
(de)
|
2016-06-09 |
2020-02-19 |
University of Leicester |
Monoklonale antikörper, zusammensetzungen und verfahren zum nachweis von mucin-ähnlichem protein (mlp) als biomarker für ovarial- und pankreaskrebs
|
WO2018112407A1
(en)
|
2016-12-15 |
2018-06-21 |
Duke University |
Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors
|
US10918734B2
(en)
|
2017-03-27 |
2021-02-16 |
Immunomedics, Inc. |
Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
|
US10799597B2
(en)
|
2017-04-03 |
2020-10-13 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
CN111630069A
(zh)
|
2017-10-13 |
2020-09-04 |
勃林格殷格翰国际有限公司 |
针对Thomsen-nouvelle(Tn)抗原的人抗体
|
WO2019090424A1
(en)
*
|
2017-11-09 |
2019-05-16 |
National Research Council Of Canada |
Antibody glycoconjugates and methods of production and use
|
IT202100003599A1
(it)
|
2021-02-17 |
2022-08-17 |
Inderst Srl |
Dispositivo di protezione per coltivazioni a spalliera
|
EP4342497A1
(de)
|
2021-05-10 |
2024-03-27 |
Kawasaki Institute of Industrial Promotion |
Antikörper mit reduzierter bindungsaffinität für antigen
|